Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Terminated 4Recruiting 3Completed 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 3Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 24Triple Negative Breast Neoplasms 11Breast Neoplasms 10Carcinoma, Transitional Cell 9Small Cell Lung Carcinoma 7Carcinoma, Renal Cell 7Carcinoma, Hepatocellular 7Neoplasm Metastasis 6Melanoma 6Colorectal Neoplasms 6Lung Neoplasms 5Recurrence 4Neoplasms 4Urinary Bladder Neoplasms 3Lymphoma, B-Cell 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Solid Tumor 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma 2Liver Neoplasms 2Leukemia, Myeloid, Acute 2Kidney Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Merkel Cell 2Brain Neoplasms 2Advanced Solid Tumor 2Urologic Neoplasms 1Urologic Diseases 1

Interventions

Dexamethasone 29Cyclophosphamide 21Rituximab 17Cytarabine 16Bortezomib 13Gemcitabine 12fludarabine 11Methotrexate 11Lenalidomide 10Filgrastim 10Vincristine 9Etoposide 9pomalidomide 8pembrolizumab 8Paclitaxel 8Azacitidine 8venetoclax 7carfilzomib 7Doxorubicin 7Docetaxel 7Cyclosporine 7Calcium Dobesilate 7Antilymphocyte Serum 7fludarabine phosphate 6Topotecan 6Temozolomide 6Radiotherapy 6Peripheral Blood Stem Cell Transplantation 6Mitoxantrone 6daratumumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Recurrence × atezolizumab × Clear all
NCT03713944 2023-03-01

Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

Big Ten Cancer Research Consortium

Phase 2 Terminated
30 enrolled 28 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT03422523 2022-08-22

ARGO

University Hospital Southampton NHS Foundation Trust

Phase 2 Terminated
53 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03465891 2021-01-12

Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
2 enrolled 6 charts
Lymphoid

Lymphoma, Recurrence

NCT03120676 2019-11-14

Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
3 enrolled 3 charts
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡